Authors
Latest:
Dr. Clark Discusses Need for Biomarkers in RCCPeter Clark, MD, professor of medicine and chair of urology, Levine Cancer Institute, Atrium Health, discusses the need for biomarkers in renal cell carcinoma.
Latest:
Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLCPeter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.
Latest:
A Call for Tackling Smoking Cessation in Cancer PatientsAlthough the entire medical community recognizes the importance of smoking cessation- both for cancer prevention and cardiopulmonary health-supporting patients in their efforts to cease smoking is generally not done well.
Latest:
Research Findings Point to Clinical Importance of Clonal HematopoiesisAlthough clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.
Latest:
Distinct Genomic Differences Evident in Younger Patients With Lung CancerClinical trial findings have implications for expanding the use of genomic testing—and thereby potentially increasing treatment options—for the younger lung cancer population.
Latest:
ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van VeldhuizenOncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.
Latest:
Peter Krein on Developments in Liquid BiopsiesPeter Krein, PhD, senior director, Medical and Scientific Affairs, QIAGEN, discusses the company's latest advancements in liquid biopsies in comparison to surgical biopsies.
Latest:
Dr. Choyke on Advancements in Imaging for Prostate CancerPeter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses advances in imaging for prostate cancer.
Latest:
Dr. Choyke on Differences Between PET Scans in Prostate CancerPeter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.
Latest:
Potential Risks of Genetic Testing in Ovarian CancerPeter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.
Latest:
Dr Martin on the Role of BTK Inhibitors in the Management of MCLPeter Martin, MD, discusses the role of BTK inhibitors in the treatment of mantle cell lymphoma.
Latest:
Dr. O'Donnell on Challenges With PD-L1 Testing in Bladder CancerPeter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses challenges with PD-L1 testing in patients with bladder cancer.
Latest:
Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate CancerPeter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.
Latest:
Dr. Dottino on the Benefit of Early-Detection Screening in Endometrial CancerPeter R. Dottino, MD, discusses the benefit of early-detection screening for endometrial cancer.
Latest:
Dr. Schmid on Activity With Neoadjuvant Pembrolizumab in TNBCPeter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Latest:
Dr Schmid on the Use of Perioperative Pembrolizumab in TNBCPeter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer.
Latest:
Dr. Soyer Discusses the Role of Technology in MelanomaPeter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.
Latest:
Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple MyelomaPeter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.
Latest:
Dr. Yu Discusses Observation Versus Treatment in Men with Prostate CancerPeter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.
Latest:
Dr Grivas on Addressing Unmet Needs in Urothelial CancerPetros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.
Latest:
ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.
Latest:
Dr. Le on Research Needed to Address Unmet Needs in mCRCPhat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.
Latest:
Dr. Febbo on the Impact of Oncotype DX Genetic Prostate ScorePhil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.
